Skip to main content
Fig. 5 | BMC Immunology

Fig. 5

From: Network pharmacology-based strategy to investigate the mechanisms of artemisinin in treating primary Sjögren’s syndrome

Fig. 5

Artemisinin reduced Th17 cells and expanded Tregs in NOD/Ltj mice. A and B Tregs and IL-17 in lymphocytes measured by flow cytometry. C The proportion of Tregs. D The proportion of IL-17. a: normal group, b: NOD/Ltj model group, c: artemisinin group, d: HCQ group (*P < 0.05 compared with the normal group; #P < 0.05 compared with the model group)

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us